- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00749788
Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels
January 31, 2013 updated by: Akros Pharma Inc.
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-302 Administered Daily for Four Weeks in Subjects With Low HDL-C Levels
The purpose of this study is to determine the effect of JTT-302 on the increase of High Density Lipoprotein-Cholesterol (HDL-C) levels when administered daily for four weeks in subjects with low HDL-C levels.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
150
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Santa Ana, California, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects with a Body Mass Index (BMI)≤ 35 kg/m2
- Subjects with the following lipid parameters at Visit 1 (screening visit) and Visit 3 (diet stabilization period):
- HDL-C ≤ 40 mg/dL (Men) and ≤ 50 mg/dL (Women)
- TG ≤ 500 mg/dL
- LDL-C ≤ 190 mg/dL
- Subjects who are generally healthy as determined by pre-study medical history, physical examination, vital signs and 12-lead ECG
Exclusion Criteria:
- Females who are pregnant or breast-feeding
- AST, ALT or total bilirubin ≥ 2.0 x ULN at Visit 1 (screening visit) or Visit 3 (diet stabilization period)
- Serum thyroid stimulating hormone (TSH) and levothyroxine (T4) outside of the central laboratory reference range at the screening visit
- Medical history of diabetes mellitus or two fasting serum glucose measurements > 126 mg/dL at the screening visit
- Subjects with hypertension, or two blood pressure measurements ≥ 140 mm Hg systolic or ≥ 90 mm Hg diastolic at the screening visit
- History of drug or alcohol abuse within 12 months of the screening visit
- Use of medications defined in the protocol within six-weeks prior to the screening visit and throughout the study
- Use of Cytochrome P450 3A4 inducers or inhibitors, as defined in the protocol within four weeks of the screening visit and throughout the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
JTT-302, 200 mg
|
JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal
|
Experimental: 2
JTT-302, 400 mg
|
JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal
|
Placebo Comparator: 3
Matching placebo tablets
|
Matching placebo tablets, oral, 30 minutes after the start of the morning meal
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent change from baseline in HDL-C at Week 4
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent change and change from baseline at week 4 in lipid parameters
Time Frame: 4 weeks
|
4 weeks
|
Evaluate the safety profile of JTT-302 when administered for 4 weeks
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2006
Primary Completion (Actual)
February 1, 2008
Study Completion (Actual)
February 1, 2008
Study Registration Dates
First Submitted
September 5, 2008
First Submitted That Met QC Criteria
September 5, 2008
First Posted (Estimate)
September 9, 2008
Study Record Updates
Last Update Posted (Estimate)
February 4, 2013
Last Update Submitted That Met QC Criteria
January 31, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AT302-U-06-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyslipidemia
-
Kowa Research Institute, Inc.CompletedMixed Dyslipidemia | Primary DyslipidemiaUnited States
-
Chong Kun Dang PharmaceuticalCompletedDyslipidemia (Fredrickson Type Ⅱa) | Dyslipidemia (Fredrickson Type Ⅱb)Korea, Republic of
-
Hanlim Pharm. Co., Ltd.RecruitingMixed DyslipidemiaKorea, Republic of
-
IlDong Pharmaceutical Co LtdNot yet recruiting
-
Arrowhead PharmaceuticalsCompletedMixed DyslipidemiaUnited States, Australia, Poland, New Zealand, Canada, Hungary
-
Provident Clinical ResearchReliant PharmaceuticalsCompleted
-
Arrowhead PharmaceuticalsActive, not recruitingMixed DyslipidemiaUnited States, Australia, Canada, New Zealand
-
Yooyoung Pharmaceutical Co., Ltd.CompletedCombined DyslipidemiaKorea, Republic of
-
Société des Produits Nestlé (SPN)CompletedPrimary DyslipidemiaChina
-
Provident Clinical ResearchReliant PharmaceuticalsUnknown
Clinical Trials on JTT-302
-
Akros Pharma Inc.Completed
-
Akros Pharma Inc.TerminatedStudy of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252Diabetes MellitusUnited States
-
Akros Pharma Inc.TerminatedType II Diabetes MellitusUnited States
-
Akros Pharma Inc.WithdrawnPulmonary Arterial Hypertension
-
Shenzhen Xbiome Biotech Co., Ltd.Beijing Improve-Quality Tech.Co., Ltd.Recruiting
-
Akros Pharma Inc.CompletedType II Diabetes MellitusUnited States, Russian Federation, Czech Republic, Hungary, Netherlands
-
Japan Tobacco Inc.CompletedType II HyperlipidaemiaNetherlands
-
Akros Pharma Inc.ICON Clinical ResearchRecruitingChronic Heart FailureUnited States
-
Akros Pharma Inc.CompletedDiabetes MellitusUnited States
-
Threshold PharmaceuticalsCompletedAcute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | High-risk Myelodysplastic Syndrome | Advanced MyelofibrosisUnited States